Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections

Pullukçu, Hüsnü; Taşbakan, Meltem; Sıpahi, Oğuz Reşat; Yamazhan, Tansu; Aydemir, Şöhret; Ulusoy, Sercan

doi:10.1016/j.ijantimicag.2006.08.039

Cited by 139 publications

(102 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…80 In this study, as well as a study demonstrating that fosfomycin was effective against extended-spectrumb-lactamase-producing E. coli UTIs, fosfomycin was administered as a 3 g dose every 48 hours for 3 total doses. 81 However, the optimal dosing and duration of therapy for CRE UTIs is unknown. 8 Polymyxins and both rifampin and the carbapenems are generally synergistic against CRE in vitro.…”

Section: Cre In Patients With Hematologic Malignancies and Haematopoimentioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

2016

View full text Add to dashboard Cite

Carbapenem-resistant Enterobacteriaceae (CRE) are a major global public health concern and pose a serious threat to immunocompromised hosts, particularly patients with hematologic malignancies and solid organ (SOT) and stem cell transplant recipients. In endemic areas, carbapenem-resistant Klebsiella pneumoniae infections occur in 1-18% of SOT recipients, and patients with hematologic malignancies represent 16-24% of all patients with CRE bacteremia. Mortality rates approaching 60% have been reported in these patient populations. Early diagnosis and rapid initiation of targeted therapy is critical in the management of immunocompromised hosts with CRE infections, as recommended empiric regimens are not active against CRE. Therapeutic options are limited by antibiotic-associated toxicities, interactions with immunosuppressive agents, and paucity of antibiotic options currently available. Prevention of CRE infection in these patients requires a multidisciplinary approach involving hospital epidemiology and antimicrobial stewardship. Large, multicenter studies are needed to develop risk-stratification tools to assist in guiding the management of these individuals.

show abstract

Section: Cre In Patients With Hematologic Malignancies and Haematopoimentioning

confidence: 99%

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

2016

View full text Add to dashboard Cite

show abstract

“…(10) 'nın yaptığı çalışmada, 3279 E. coli izolatında %2.2 olarak tespit etmişlerdir. Ülkemizde yapılan diğer çalış-malarda da %0-11.5 arasında değişen oranlarda FT direnci bildirilmektedir (11)(12)(13)(14)(15)(16)(17)(18)(19) .…”

Section: Discussionunclassified

Investigation of Fosfomycin Trometamol Susceptibility in Escherichia coli Strains Isolated from Urinary Tract Infections

İrvem¹,

Küçük²,

Pala³

et al. 2016

TMCD

View full text Add to dashboard Cite

SUMMARY Investigation of Fosfomycin Trometamol Susceptibility in Escherichia coli Strains Isolated from Urinary Tract Infections Objective: Escherichia coli is the most common microorganism isolated from both community and hospital-acquired urinary tract infections. In our study, it was aimed to investigate the extended spectrum beta lactamase (ESBL) positivity and fosfomycin trometamol (FT) resistance rates in E. coli strains isolated from urine cultures sent to microbiology laboratory of our hospital. Materials and Methods: The identification and antibiotic

show abstract

“…Pullukçu ve ark. [19] 18 yaşından büyük, üriner sistem yakınması olan, kültüründe GSBL (+) E. coli izole edilen yatan ve ayaktan hasta grubunda fosfomisinin klinik ve mikrobiyolojik etkinliğini araştırmışlardır. Klinik başarıyı %94,3, mikrobiyolojik başarıyı %78,5 olarak tespit ederek, fosfomisinin GSBL üreten E. coli'ye bağlı alt ÜSE'lerin tedavisinde etkili, ucuz alternatif bir tedavi olduğunu belirtmişlerdir.…”

Section: Discussionunclassified

In vitro Susceptibility Analysis of Escherichia coli Strains Isolated from Urinary Tract Infections to Fosfomycin, Nitrofurantoin and Ciprofloxacin

Soydan¹,

Karadağ²,

Çalışkan³

et al. 2015

mjima

View full text Add to dashboard Cite

Giriş: Escherichia coli komplike olmayan alt üriner sistem enfeksiyonlarından (ÜSE) en sık izole edilen mikroorganizmadır. E. coli kökenlerinde yüksek siprofloksasin direnci ve artmış genişlemiş spektrumlu beta-laktamaz (GSBL) üretimi, alternatif tedavi arayışlarını gündeme getirmiştir. Gereç ve Yöntem:Çalışmamıza Derince Eğitim ve Araştırma Hastanesi'nde, farklı departmanlardan laboratuvarımıza gönderilen, ÜSE tanısı almış hastaların idrar örneklerinden izole edilen 366 E. coli kökeni dahil edildi. Bulgular:Çalışmaya dahil edilen 366 suşun 90'ının (%24,6) GSBL pozitif, 276'sının (%75,4) ise GSBL negatif olduğu görüldü. GSBL (+) ve GSBL (-) E. coli suşlarında duyarlılık oranları sırasıyla, fosfomisine %100 ve %99,7, nitrofurantoine %80 ve %90,6, siprofloksasine %40 ve %80,8 olarak bulundu. Sonuç:Çalışmaya alınan E. coli suşlarında siprofloksasin direncinin yüksek, fosfomisin ve nitrofurantoin direncinin düşük olduğu tespit edilmiştir.Bu nedenle hastanemize başvuran hastalarda E. coli oluşturulan non-komplike ÜSE'lerin tedavisinde fosfomisin ve nitrofurantoinin ampirik tedavi amacıyla kullanılabileceği kanaatine varılmıştır.Anahtar Kelimeler: İdrar yolu enfeksiyonu, genişlemiş spektrumlu beta-laktamaz, Escherichia coli, fosfomisin, nitrofurantoin, siprofloksasin ÖzIntroduction: Escherichia coli is the most commonly isolated microorganism from uncomplicated lower urinary tract infections (UTI). The occurrence of high ciprofloxacin resistance and production of extended spectrum beta-lactamase (ESBL) in E. coli isolates have led the researchers to investigate new treatment approaches. Materials and Methods: A total of 366 E. coli strains isolated from urine samples of patients with the diagnosis of UTI, who were referred to our laboratory from different departments at our hospital, were included in this study. Results: Ninety (24.6%) isolates were found to be ESBL-positive and 276 (75.4%) were ESBL-negative. The rates of susceptibility to fosfomycin, nitrofurantoin and ciprofloxacin in ESBL-positive and ESBL-negative E. coli strains were found to be 100% and 99.7%, 80% and 90.6%, and 40% and 80.8%, respectively. Conclusion: In conclusion, ciprofloxacin resistance was high and resistance to fosfomycin and nitrofurantoin was very low in E. coli. Therefore, we assume that fosfomycin and nitrofurantoin can be used as empiric therapy for uncomplicated UTI caused by E. coli. Keywords: Urinary tract infection, extended spectrum beta lactamase, Escherichia coli, fosfomycin, nitrofurantoin, ciprofloxacin AbstractIn vitro Susceptibility Analysis of Escherichia coli Strains Isolated from Urinary Tract Infections to Fosfomycin, Nitrofurantoin and Ciprofloxacin

show abstract

Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections

Cited by 139 publications

References 12 publications

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Carbapenem-resistant Enterobacteriaceae in special populations: Solid organ transplant recipients, stem cell transplant recipients, and patients with hematologic malignancies

Investigation of Fosfomycin Trometamol Susceptibility in Escherichia coli Strains Isolated from Urinary Tract Infections

In vitro Susceptibility Analysis of Escherichia coli Strains Isolated from Urinary Tract Infections to Fosfomycin, Nitrofurantoin and Ciprofloxacin

Contact Info

Product

Resources

About